Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, septembre 14
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Alnylam Pharmaceuticals Inc
ALNY
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$249.99
1.31
0.53%
À la clôture: Sep 14, 5:00 PM EST
$249.99
N/A
Après les heures: 4:00 PM EST
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Alnylam Pharmaceuticals Financials
Alnylam Pharmaceuticals (ALNY) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.
Vandana Singh
PRO
Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est
Alnylam Pharmaceuticals (NASDAQ:ALNY) lowers FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.275 billion-$5.725 billion vs $5.580 billion estimate.
Benzinga Newsdesk
PRO
Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.84 per share which beat the analyst consensus estimate of $1.55 by 18.71 percent. This is a 475 percent increase over earnings of $0.32 per share
Benzinga Newsdesk
PRO
Alnylam Pharmaceuticals Affirms FY2026 Sales Guidance of $5.300B-$5.800B vs $5.545B Est
Alnylam Pharmaceuticals (NASDAQ:ALNY) affirms FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.300 billion-$5.800 billion vs $5.545 billion estimate.
Benzinga Newsdesk
PRO
Alnylam Pharmaceuticals Q1 Adj. EPS $1.99 Beats $0.93 Estimate, Sales $1.167B Beat $1.114B Estimate
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $0.93 by 113.98 percent. This is a 586.21 percent increase over earnings of $0.29 per
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
Privacy Manager